The 3 day long Masterclass in Clinical Trials and Medicine Development is organized by Terrapinn Ltd and will be held during February 22 – 24, 2017 in New York, NY.

 

The Masterclass in Clinical Trials is designed to provide insight into new business opportunities in the field of clinical trials and the development process of new healthcare interventions. The course will provide insight into complex cross-disciplinary integrated health within the process of diffusion of new medical interventions, from pharmaceuticals, medical devices, diagnostics, surgical interventions to dietary supplements.

 

Dr. Mehling will attend the course together with Marina Manvelyan, PhD., clinicial research scientist of Blue Horizon International.

 Dr Mehling said : “I am looking forward to the lectures and practical sessions that will cover the key issues to be considered in design, conduct, analysis and reporting, with a focus on major clinical trials which directly influence clinical practice.”

 

The course will be lead by Carl Naraynassamy. His clinical research career includes work for Aventis, Kendle Inc and GlaxoWellcome. His professional association work includes the Association of Clinical Research Professionals & the Academy of Pharmaceutical Physicians and Investigators. His academic work includes Hibernia College, Dublin and The London School of Tropical Medicine, London University.

 

The participants will learn how new drugs are discovered, learn about the new and developing technologies, understand what data is needed before clinical trials can start, become familiar with the regulatory and ethics processes, see what is needed for a target product profile, evaluate the four phases of clinical trials, see how planning and logistical issues are critical to the successful running of trials, learn how to write protocol, see the challenges of data management and statistics, appreciate the importance of planning to collect and analyse safety data and learn by experience and carry out a simulated clinical trial.

Terrapinn offers something unique in professional training. Their curriculum is presented by a global faculty of experienced practitioners with a passion for teaching and sharing hard-won industry insights. Their courses cover the most important markets and disciplines and clients can bring along their own company models for practical and confidential advice. 

Brian Mehling, M.D. and Blue Horizon International (BHI) have recently been making headlines – from being featured in VOGUE magazine, news of the preview screening of their stem cell documentary “Stem Cells – The Next Frontier,” which was screened during the Tribeca Film Festival in April, to its screening at the Cannes Film Festival on May 25th. There was also a well-attended networking event that followed the next day to celebrate the successful screening in Cannes.

“Stem Cells – The Next Frontier” is a documentary about stem cell research being the next frontier in medicine, but many have only the narrowest understanding of what it is, what it can do, and why it isn’t explored to its full potential in the United States.  The film aspires to uncover the world of stem cells and to answer most common questions and bring some light into this topic. Furthermore it explores what exactly stem cells are, as well as their potential to reshape the medical world. Executive producer of the documentary is Brian Mehling, M.D., Production: Ralph Moffetone and John-David Grayson, Editor: John-David Grayson and Supervisor: Melody London.

“It was a great night, so many people came from different corners of the world. It was truly a unique event, thanks to our special guest, Jermaine Jackson, the brother of the late Michael Jackson. We were so grateful to have him,” said Dr. Mehling.

The documentary was made with the idea of bringing the topic of stem cells and stem cell therapies to wider audiences, so its mission is definitely getting accomplished. Even though it took several years for the movie to be completed, now it’s time for people to see it and discover the stem cells for themselves.

The documentary contains testimonials of the physicians, the researchers and the patients who have participated in the BHI program over the years. Dr. Mehling hopes that through education, these advanced therapies will be available sooner rather than later to people in need.

Dr. Mehling added: “We are looking to expand world-wide, so being here during the Cannes Film Festival is a great way to meet new people and introduce them to our program. BHI partners with advanced facilities for research in the very latest in surgical and medical technology, including both autologous stem cell and placental cord blood. This technology allows stem cells obtained from the patient’s own body or in some cases from placental cord blood to be used. To date, we have completed more than 1,000 stem cell injections. “

Blue Horizon International  is a healthcare management company with a unique concept. We provide the highest quality care and service available in surgical and medical treatments globally, the most advanced technologies currently available in stem cell therapies, all while giving back to the children in the communities we serve.  

We have safely and efficiently performed more than 3,000 stem cell research procedures to date. We are the only treatment provider approved and associated with The Wuhan University Department of Medicine, The Biochemistry Institute of Wuhan University. We are fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital near Bratislava, Slovakia.

Industrial Motion Pictures is a creative film company founded by Dr. Brian Mehling. IMP, in association with Mehling Studios brings creative and innovative films to life. IMP has been associated with films such as: Tiny Tears, Italy’s Forgotten Earthquake, BreadCrumbs, Dead Calling, A Smile for Bow and Stem Cells- The Next Frontier.  IMP was originally founded in the 1950’s.  Our mantra is not based on profit, but rather, we emphasize and focus on the impact our films bring to communities on a diverse level. 

The Cannes International Film Festival is an annual film festival held in Cannes, France, which previews new films of all genres, including documentaries, from around the world. Founded in 1946, it is one of the most prestigious and publicised film festivals in the world. The invitation-only festival is held annually (usually in May) at the Palais des Festivals et des Congrès.

Blue Horizon International team to attend Clinical Trials Masterclass in New York

 

Brian Mehling, M.D. and Marina Manvelyan, Ph.D., will attend a three-day long Masterclass in Clinical Trials and Medicine Development from February 22 – 24, 2017 in New York, NY.

 

The Masterclass in Clinical Trials is designed to provide insight into new business opportunities in the field of clinical trials and the development process of new healthcare interventions. The course will provide insight into complex cross-disciplinary integrated health within the process of diffusion of new medical interventions, from pharmaceuticals, medical devices, diagnostics, surgical interventions to dietary supplements.

 

Dr. Mehling will attend the course with Marina Manvelyan, PhD., Blue Horizon International’s clinical research scientist.

 Dr Mehling said, “I am looking forward to the lectures and practical sessions that will cover the key issues to be considered in design, conduct, analysis and reporting, with a focus on major clinical trials which directly influence clinical practice.”

 

The course will be led by Carl Naraynassamy. His clinical research career includes work for Aventis, Kendle Inc and GlaxoWellcome. His professional association work includes the Association of Clinical Research Professionals & the Academy of Pharmaceutical Physicians and Investigators. His academic work includes Hibernia College, Dublin and The London School of Tropical Medicine, London University.

 

The participants will discover new approaches in drug developing technologies and clinical trial management.

 

BHI Therapeutic Sciences, LLC is currently offering cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Slovakia and is fully licensed by the Ministry of Health of the Slovak Republic. For more information, please visit www.bhisciences.com.

 

Brian Mehling, M.D., US orthopedic trauma surgeon, stem cell researcher and founder of Blue Horizon International to attend World Economic Forum in Davos.

 

Brian Mehling, M.D., world-renowned stem cell researcher, board-certified orthopedic trauma surgeon, and founder of Blue Horizon International (BHI), will be attending the 47th Annual World Economic Forum (WEF) in Davos from January 17-20, 2017. This will be Dr. Mehling’s fifth year attending the global conference.

The theme of this year’s forum is Responsive and Responsible Leadership; over half of the program’s 400 sessions will address strategies for fostering greater social inclusion and human development. One-third of the 3,000 participants come from outside Europe and North America, another one-third will represent stakeholder groups outside business and government. The Annual Meeting 2017 welcomes members from a wide range of other Forum communities, including the heads of all leading international organizations, leaders from civil society organizations including NGOs, labor organizations and faith-based organizations.

Dr. Mehling will be available onsite to share insights on the current and upcoming breakthroughs in regard to cellular and regenerative medicine and stem cell research as it relates to the technology revolution. “The ‘miracle drug’ we are all searching for may not be a drug at all. It may be our own cells. Stem cells have the potential to treat better than any pill or drug, because it directly gives the body exactly what is missing – healthy cells,” said Dr. Mehling, “Regenerative medicine is not the future, it is the present.”

“The world around us is changing at unprecedented speed. At this tipping point, our traditional concepts of society, meaningful employment and the nation state are challenged, and many understandably feel insecure or even threatened. A new model of responsive and responsible leadership is needed to allow us to address the challenges the world faces, from security to the Fourth Industrial Revolution, with long-term, action-oriented thinking and solidarity on a national and global level,” said Professor Klaus Schwab, Founder and Executive Chairman, World Economic Forum.

In addition to being the most comprehensive meeting of ministerial delegations in the world, with over 70 countries including all G20 countries participating, this year’s Meeting will include the participation of the new Secretary-General of the United Nations, António Guterres, along with heads of key international organizations. Forum activities throughout the year promote projects and initiatives that support the UN Sustainable Development Goals. The Annual Meeting 2017 will be opened by President Xi Jinping of China, who will be accompanied by the largest delegation of Chinese officials since the country first participated in the Annual Meeting in 1979.

Onsite interviews with Dr. Mehling at WEF will be available upon request and handled on a first-come, first-served basis. To learn more about WEF, please visit: http://www.weforum.org

About Blue Horizon International 
Blue Horizon International is a healthcare consulting company with a unique mission that combines treatment, research and philanthropic efforts. Across the globe quality care and services for medical treatments are provided along with resources needed to assist children and adults who are medically underserved. For more information please visit Blue Horizon International at http://www.bluehorizoninternational.com.